Amylyx Pharmaceuticals Statistics
Total Valuation
AMLX has a market cap or net worth of $275.73 million. The enterprise value is $43.91 million.
Important Dates
The last earnings date was Thursday, November 7, 2024, before market open.
| Earnings Date | Nov 7, 2024 |
| Ex-Dividend Date | n/a |
Share Statistics
AMLX has 68.08 million shares outstanding. The number of shares has decreased by -1.59% in one year.
| Current Share Class | 68.08M |
| Shares Outstanding | 68.08M |
| Shares Change (YoY) | -1.59% |
| Shares Change (QoQ) | +0.10% |
| Owned by Insiders (%) | 10.22% |
| Owned by Institutions (%) | 57.62% |
| Float | 41.93M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 1.40 |
| Forward PS | n/a |
| PB Ratio | 1.41 |
| P/TBV Ratio | 1.41 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 0.22 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 4.55, with a Debt / Equity ratio of 0.01.
| Current Ratio | 4.55 |
| Quick Ratio | 4.38 |
| Debt / Equity | 0.01 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -84.43% and return on invested capital (ROIC) is -50.10%.
| Return on Equity (ROE) | -84.43% |
| Return on Assets (ROA) | -43.44% |
| Return on Capital (ROIC) | -50.10% |
| Revenue Per Employee | $511,680 |
| Profits Per Employee | -$675,693 |
| Employee Count | 384 |
| Asset Turnover | 0.55 |
| Inventory Turnover | n/a |
Taxes
In the past 12 months, AMLX has paid $1.99 million in taxes.
| Income Tax | 1.99M |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -71.03% in the last 52 weeks. The beta is -0.68, so AMLX's price volatility has been lower than the market average.
| Beta (5Y) | -0.68 |
| 52-Week Price Change | -71.03% |
| 50-Day Moving Average | 5.04 |
| 200-Day Moving Average | 2.95 |
| Relative Strength Index (RSI) | 36.50 |
| Average Volume (20 Days) | 786,141 |
Short Selling Information
The latest short interest is 1.45 million, so 2.13% of the outstanding shares have been sold short.
| Short Interest | 1.45M |
| Short Previous Month | 1.53M |
| Short % of Shares Out | 2.13% |
| Short % of Float | 3.46% |
| Short Ratio (days to cover) | 1.00 |
Income Statement
In the last 12 months, AMLX had revenue of $196.49 million and -$259.47 million in losses. Loss per share was -$3.83.
| Revenue | 196.49M |
| Gross Profit | -99.82M |
| Operating Income | -249.29M |
| Pretax Income | -162.36M |
| Net Income | -259.47M |
| EBITDA | -248.25M |
| EBIT | -249.29M |
| Loss Per Share | -$3.83 |
Full Income StatementBalance Sheet
The company has $234.40 million in cash and $2.57 million in debt, giving a net cash position of $231.83 million or $3.41 per share.
| Cash & Cash Equivalents | 234.40M |
| Total Debt | 2.57M |
| Net Cash | 231.83M |
| Net Cash Per Share | $3.41 |
| Equity (Book Value) | 196.20M |
| Book Value Per Share | 2.86 |
| Working Capital | 191.35M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$95.09 million and capital expenditures -$36.70 million, giving a free cash flow of -$131.78 million.
| Operating Cash Flow | -95.09M |
| Capital Expenditures | -36.70M |
| Free Cash Flow | -131.78M |
| FCF Per Share | -$1.94 |
Full Cash Flow StatementMargins
Gross margin is -50.80%, with operating and profit margins of -126.88% and -132.05%.
| Gross Margin | -50.80% |
| Operating Margin | -126.88% |
| Pretax Margin | -131.04% |
| Profit Margin | -132.05% |
| EBITDA Margin | -126.34% |
| EBIT Margin | -126.88% |
| FCF Margin | n/a |
Dividends & Yields
AMLX does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | 1.59% |
| Shareholder Yield | 1.59% |
| Earnings Yield | -94.10% |
| FCF Yield | -47.79% |
Dividend DetailsAnalyst Forecast
The average price target for AMLX is $7.60, which is 87.65% higher than the current price. The consensus rating is "Buy".
| Price Target | $7.60 |
| Price Target Difference | 87.65% |
| Analyst Consensus | Buy |
| Analyst Count | 7 |
| Revenue Growth Forecast (5Y) | -24.58% |
| EPS Growth Forecast (5Y) | n/a |
Stock ForecastsStock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
AMLX has an Altman Z-Score of 1.25 and a Piotroski F-Score of 1. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | 1.25 |
| Piotroski F-Score | 1 |